Clinical trial
Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple…
NCT00006219 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00006219 |
|---|---|
| Title | Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma |
| Official title | A Phase II Clinical Trial of Dehydroepiandrosterone and Biaxin in Monoclonal Gammopathy of Undetermined and Borderline Significance |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | clarithromycin, prasterone |
| Start date | Aug 1, 2000 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: